Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

Publisher Name :
Date: 17-Apr-2018
No. of pages: 202
Inquire Before Buying

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018, provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 8, 11, 31, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 7 molecules, respectively.

Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Clostridium difficile Associated Disease) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

Table of Contents
Table of Contents 2
Introduction 5
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview 6
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development 7
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 21
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 29
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles 48
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 174
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 179
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 180
Appendix 192

List of Tables
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Chain Biotechnology Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Ferring International Center SA, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmuneBiotech AB, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inspyr Therapeutics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics plc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Vitality Biopharma Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2018 (Contd..2), H1 2018

List of Figures
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs